Your browser doesn't support javascript.
loading
Early positron emission tomography/computed tomography as a predictor of response after CTL019 chimeric antigen receptor -T-cell therapy in B-cell non-Hodgkin lymphomas.
Shah, Nirav N; Nagle, Sarah J; Torigian, Drew A; Farwell, Michael D; Hwang, Wei-Ting; Frey, Noelle; Nasta, Sunita D; Landsburg, Daniel; Mato, Anthony; June, Carl H; Schuster, Stephen J; Porter, David L; Svoboda, Jakub.
Affiliation
  • Shah NN; Medical College of Wisconsin, Division of Hematology/Oncology, Milwaukee, Wisconsin, USA. Electronic address: nishah@mcw.edu.
  • Nagle SJ; Center for Hematologic Malignancies, The Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, USA.
  • Torigian DA; Department of Radiology, Hospital of the University of Pennsylvania, Pennsylvania, USA.
  • Farwell MD; Department of Radiology, Hospital of the University of Pennsylvania, Pennsylvania, USA.
  • Hwang WT; Lymphoma Program at the Abramson Cancer Center and the Division of Hematology-Oncology Perelman School of Medicine, University of Pennsylvania, Pennsylvania, USA.
  • Frey N; Lymphoma Program at the Abramson Cancer Center and the Division of Hematology-Oncology Perelman School of Medicine, University of Pennsylvania, Pennsylvania, USA.
  • Nasta SD; Lymphoma Program at the Abramson Cancer Center and the Division of Hematology-Oncology Perelman School of Medicine, University of Pennsylvania, Pennsylvania, USA.
  • Landsburg D; Lymphoma Program at the Abramson Cancer Center and the Division of Hematology-Oncology Perelman School of Medicine, University of Pennsylvania, Pennsylvania, USA.
  • Mato A; Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • June CH; Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Schuster SJ; Lymphoma Program at the Abramson Cancer Center and the Division of Hematology-Oncology Perelman School of Medicine, University of Pennsylvania, Pennsylvania, USA; Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Porter DL; Lymphoma Program at the Abramson Cancer Center and the Division of Hematology-Oncology Perelman School of Medicine, University of Pennsylvania, Pennsylvania, USA; Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Svoboda J; Lymphoma Program at the Abramson Cancer Center and the Division of Hematology-Oncology Perelman School of Medicine, University of Pennsylvania, Pennsylvania, USA.
Cytotherapy ; 20(12): 1415-1418, 2018 12.
Article in En | MEDLINE | ID: mdl-30385043
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Language: En Journal: Cytotherapy Journal subject: TERAPEUTICA Year: 2018 Document type: Article Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Language: En Journal: Cytotherapy Journal subject: TERAPEUTICA Year: 2018 Document type: Article Country of publication: